Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Biogen
- Study ID
- NCT00168740
- Phase
- PHASE3
- Status
- Completed
Conditions
- Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- rituximab — DRUG
Study Details
Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.
Key Dates
- First listed
- Sep 15, 2005
- Start date
- Apr 30, 1995
- Status verified
- Sep 2005
Study Design
- Enrollment
- 150 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
overall response rate